Lebrikizumab may benefit a subset of patients with asthma
- Correspondence to Dr Sasiharan Sithamparanathan, ST3, King George Hospital, Barley Lane, Goodmayes, Essex IG3 8YB, UK;
Interleukin 13 (IL-13), a cytokine of type 2 helper T cells, may contribute to the heterogeneity of asthma in terms of clinical course and response to treatment. IL-13 leads to the production of periostin, a protein that may cause airway remodelling.
In this randomised, double-blind, placebo-controlled study, lebrikizumab, a monoclonal antibody that binds to IL-13 thereby inhibiting …